Type of non Hodgkin's lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...

Read More

How effective is rituximab plus gemcitabine and oxaliplatin for patients with refractory/relapsed DLBCL?

How effective is rituximab plus gemcitabine and oxaliplatin for patients with refractory/relapsed DLBCL?

Posted by on May 23, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the efficacy and safety of R-GemOx (rituximab, gemcitabine, and oxaliplatin) for the treatment of patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The authors concluded that R-GemOx is an effective treatment regimen in patients ineligible for intensive treatment. Some...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Posted by on Dec 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients.  Some background B-NHL is a type of...

Read More

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Posted by on Dec 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).   This study concluded that this combination was safe and effective in these...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.   This study concluded that this treatment path is feasible and a good treatment alternative for these patients.   Some background Allogenic...

Read More

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More

Total body irradiation and risk of breast cancer after transplantation in patients with leukemia-lymphoma

Total body irradiation and risk of breast cancer after transplantation in patients with leukemia-lymphoma

Posted by on Oct 3, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the association between total body irradiation and further breast cancer diagnosis in patients treated with blood or marrow transplantation for leukemia-lymphoma.  This study concluded that there is an association between the total body irradiation and an increased risk of breast cancer in certain...

Read More

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Posted by on Sep 29, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT).  Some background Lymphoma is a cancer that...

Read More